276 related articles for article (PubMed ID: 31160716)
21. An update on genetically engineered mouse models of pancreatic neuroendocrine neoplasms.
Gaspar TB; Lopes JM; Soares P; Vinagre J
Endocr Relat Cancer; 2022 Dec; 29(12):R191-R208. PubMed ID: 36197786
[TBL] [Abstract][Full Text] [Related]
22. Chemopreventive and chemotherapeutic actions of mTOR inhibitor in genetically defined head and neck squamous cell carcinoma mouse model.
Sun ZJ; Zhang L; Hall B; Bian Y; Gutkind JS; Kulkarni AB
Clin Cancer Res; 2012 Oct; 18(19):5304-13. PubMed ID: 22859719
[TBL] [Abstract][Full Text] [Related]
23. Loss of Activin Receptor Type 1B Accelerates Development of Intraductal Papillary Mucinous Neoplasms in Mice With Activated KRAS.
Qiu W; Tang SM; Lee S; Turk AT; Sireci AN; Qiu A; Rose C; Xie C; Kitajewski J; Wen HJ; Crawford HC; Sims PA; Hruban RH; Remotti HE; Su GH
Gastroenterology; 2016 Jan; 150(1):218-228.e12. PubMed ID: 26408346
[TBL] [Abstract][Full Text] [Related]
24. Targeting β-catenin signaling for therapeutic intervention in MEN1-deficient pancreatic neuroendocrine tumours.
Jiang X; Cao Y; Li F; Su Y; Li Y; Peng Y; Cheng Y; Zhang C; Wang W; Ning G
Nat Commun; 2014 Dec; 5():5809. PubMed ID: 25517963
[TBL] [Abstract][Full Text] [Related]
25. Targeting notch pathway enhances rapamycin antitumor activity in pancreas cancers through PTEN phosphorylation.
Vo K; Amarasinghe B; Washington K; Gonzalez A; Berlin J; Dang TP
Mol Cancer; 2011 Nov; 10():138. PubMed ID: 22074495
[TBL] [Abstract][Full Text] [Related]
26. DNA methylation profiling in MEN1-related pancreatic neuroendocrine tumors reveals a potential epigenetic target for treatment.
Conemans EB; Lodewijk L; Moelans CB; Offerhaus GJA; Pieterman CRC; Morsink FH; Dekkers OM; de Herder WW; Hermus AR; van der Horst-Schrivers AN; Drent ML; Bisschop PH; Havekes B; Brosens LAA; Dreijerink KMA; Borel Rinkes IHM; Timmers HTM; Valk GD; Vriens MR
Eur J Endocrinol; 2018 Sep; 179(3):153-160. PubMed ID: 29903750
[TBL] [Abstract][Full Text] [Related]
27. Three types of metaplasia model through Kras activation, Pten deletion, or Cdh1 deletion in the gastric epithelium.
Kinoshita H; Hayakawa Y; Konishi M; Hata M; Tsuboi M; Hayata Y; Hikiba Y; Ihara S; Nakagawa H; Ikenoue T; Ushiku T; Fukayama M; Hirata Y; Koike K
J Pathol; 2019 Jan; 247(1):35-47. PubMed ID: 30168144
[TBL] [Abstract][Full Text] [Related]
28. Survival benefit with proapoptotic molecular and pathologic responses from dual targeting of mammalian target of rapamycin and epidermal growth factor receptor in a preclinical model of pancreatic neuroendocrine carcinogenesis.
Chiu CW; Nozawa H; Hanahan D
J Clin Oncol; 2010 Oct; 28(29):4425-33. PubMed ID: 20823411
[TBL] [Abstract][Full Text] [Related]
29. The impact of coexisting genetic mutations on murine optic glioma biology.
Kaul A; Toonen JA; Gianino SM; Gutmann DH
Neuro Oncol; 2015 May; 17(5):670-7. PubMed ID: 25246427
[TBL] [Abstract][Full Text] [Related]
30. c-MET inhibition: novel treatment for sporadic and MEN1-associated GEP NETs.
Lee ME; Tepede AA; Mandl A; Weinstein LS; Del Rivero J; Agarwal SK; Blau JE
J Mol Endocrinol; 2020 Aug; 65(2):R1-R17. PubMed ID: 32384260
[TBL] [Abstract][Full Text] [Related]
31. PHLDA3 is a novel tumor suppressor of pancreatic neuroendocrine tumors.
Ohki R; Saito K; Chen Y; Kawase T; Hiraoka N; Saigawa R; Minegishi M; Aita Y; Yanai G; Shimizu H; Yachida S; Sakata N; Doi R; Kosuge T; Shimada K; Tycko B; Tsukada T; Kanai Y; Sumi S; Namiki H; Taya Y; Shibata T; Nakagama H
Proc Natl Acad Sci U S A; 2014 Jun; 111(23):E2404-13. PubMed ID: 24912192
[TBL] [Abstract][Full Text] [Related]
32. Global expression profiling of murine MEN1-associated tumors reveals a regulatory role for menin in transcription, cell cycle and chromatin remodelling.
Mould AW; Duncan R; Serewko-Auret M; Loffler KA; Biondi C; Gartside M; Kay GF; Hayward NK
Int J Cancer; 2007 Aug; 121(4):776-83. PubMed ID: 17455252
[TBL] [Abstract][Full Text] [Related]
33. Chemoprevention with Somatuline© Delays the Progression of Pancreatic Neuroendocrine Neoplasms in a Mouse Model of Multiple Endocrine Neoplasia Type 1 (MEN1).
Lopez CL; Joos B; Bartsch DK; Manoharan J; Albers M; Slater EP; Bollmann C; Roth S; Bayer A; Fendrich V
World J Surg; 2019 Mar; 43(3):831-838. PubMed ID: 30600364
[TBL] [Abstract][Full Text] [Related]
34. Well-differentiated G1 and G2 pancreatic neuroendocrine tumors: a meta-analysis of published expanded DNA sequencing data.
Andersen KØ; Detlefsen S; Brusgaard K; Christesen HT
Front Endocrinol (Lausanne); 2024; 15():1351624. PubMed ID: 38868744
[TBL] [Abstract][Full Text] [Related]
35. Loss of MEN1 function impairs DNA repair capability of pancreatic neuroendocrine tumors.
Lakiza O; Lutze J; Vogle A; Williams J; Abukdheir A; Miller P; Liao C'; Pitroda SP; Martinez C; Olivas A; Setia N; Kron SJ; Weichselbaum RR; Keutgen XM
Endocr Relat Cancer; 2022 Mar; 29(4):225-239. PubMed ID: 35171113
[TBL] [Abstract][Full Text] [Related]
36. Parathyroid gland-specific deletion of the mouse Men1 gene results in parathyroid neoplasia and hypercalcemic hyperparathyroidism.
Libutti SK; Crabtree JS; Lorang D; Burns AL; Mazzanti C; Hewitt SM; O'Connor S; Ward JM; Emmert-Buck MR; Remaley A; Miller M; Turner E; Alexander HR; Arnold A; Marx SJ; Collins FS; Spiegel AM
Cancer Res; 2003 Nov; 63(22):8022-8. PubMed ID: 14633735
[TBL] [Abstract][Full Text] [Related]
37. DAXX/ATRX and MEN1 genes are strong prognostic markers in pancreatic neuroendocrine tumors.
Park JK; Paik WH; Lee K; Ryu JK; Lee SH; Kim YT
Oncotarget; 2017 Jul; 8(30):49796-49806. PubMed ID: 28591701
[TBL] [Abstract][Full Text] [Related]
38. Epigenetic regulation of the lncRNA MEG3 and its target c-MET in pancreatic neuroendocrine tumors.
Modali SD; Parekh VI; Kebebew E; Agarwal SK
Mol Endocrinol; 2015 Feb; 29(2):224-37. PubMed ID: 25565142
[TBL] [Abstract][Full Text] [Related]
39. GFAP-directed Inactivation of Men1 Exploits Glial Cell Plasticity in Favor of Neuroendocrine Reprogramming.
Duan S; Sawyer TW; Sontz RA; Wieland BA; Diaz AF; Merchant JL
Cell Mol Gastroenterol Hepatol; 2022; 14(5):1025-1051. PubMed ID: 35835391
[TBL] [Abstract][Full Text] [Related]
40. Targeting Focal Adhesion Kinase and Resistance to mTOR Inhibition in Pancreatic Neuroendocrine Tumors.
François RA; Maeng K; Nawab A; Kaye FJ; Hochwald SN; Zajac-Kaye M
J Natl Cancer Inst; 2015 Aug; 107(8):. PubMed ID: 25971297
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
